AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript

AVANIR Pharmaceuticals, Inc. ( AVNR)

F1Q12 Earnings Call

February 7, 2012 4:30 PM ET

Executives

Ian Clements – IR

Keith Katkin – President and CEO

Christine Ocampo – VP, Finance

Joao Siffert – SVP, Research and Development

Randall Kaye – SVP, Clinical Research and Medical Affairs and Chief Medical Officer

Analysts

Charles Duncan – JMP Securities

Ritu Baral – Canaccord

Thomas Wei – Jefferies

Christopher James – MLV & Company

Carol Werther – Summer Street

Gregory Wade – Wedbush

Presentation

Operator

Good afternoon. My name is Nathalie and I will be your conference operator today. At this time, I would like to welcome everyone to the AVANIR Fiscal 2012 First Quarter Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session.

(Operator Instructions)

Thank you. Mr. Ian Clements, you may begin your conference.

Ian Clements

Thank you, operator and good afternoon, everybody. I’d like to welcome you to our conference call to discuss our financial and operating results for fiscal 2012 first quarter. Today is the one-year anniversary of the commercial launch of NUEDEXTA. Hence this is an opportune time to discuss the success of our initial launch phase and the strong momentum heading into 2012.

We have recently undertaken several initiatives to help accelerate revenue growth and deliver meaningful returns to our shareholders. To discuss our results and these initiatives, I’m joined by Keith Katkin, President and Chief Executive Officer, who will provide a strategic overview of our performance, Christine Ocampo, Vice President of Finance, who will provide additional details on our financial performance during the quarter and Dr. Joao Siffert, Senior Vice President, Research and Development who will provide an R&D update. For the Q&A portion of today’s call, we will also be joined by Dr. Randall Kaye, Chief Medical Officer.

If you liked this article you might like

Develop Biotech 'Buy-Sell' Strategy

Develop Biotech 'Buy-Sell' Strategy

Two Small-Cap Biotechs To Consider

Two Small-Cap Biotechs To Consider

Next Year's Stock Returns: 5% or 15%?

Next Year's Stock Returns: 5% or 15%?

Updating a Small Speculative Play

Updating a Small Speculative Play

Three Large-Cap Growth Stocks

Three Large-Cap Growth Stocks